A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

NCT02821754 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

NIH

Sponsor class

Conditions

Biliary Tract Neoplasms
Liver Cancer
Hepatocellular Carcinoma
Cholangiocarcinoma
Bile Duct Cancer

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
PROCEDURE: Trans-arterial Catheter Chemoembolization (TACE)
PROCEDURE: Radiofrequency Ablation (RFA)
PROCEDURE: Cryoablation

Sponsor

National Cancer Institute (NCI)